A Phase 2 interventional study of Formoterol and Salmeterol in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 17 sites in 3 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2012-10-25.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. formoterol · Pulmonary Disease, Chronic Obstructive.
Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, this one is the 46th largest by enrollment, is one of 3 that started in 2010, is one of 12 in phase 2, and was the 29th registered.
5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →3 of the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
University of Tennessee Graduate School of Medicine · Sites in United States
Ages 40+
By country, each count listing its studies:
formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 109 is above the median of 62 across 3,845 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 120 across the 89 interventional studies. Of the 80 that completed or were terminated, 38 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 89 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca: 14 open now, 15 under way, 4 of them phase 3. Of 264 finished, 127 (48%) have results posted.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 108th largest by enrollment of the 194 interventional ones that give a count, is one of 25 that started in 2010, is one of 54 in phase 2, and was the 62nd registered.
AstraZeneca’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 1999.
1 of the studies testing formoterol in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 284 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Formoterol Turbuhaler 9 μg and Placebo Diskus first, then Salmeterol Diskus 50 μg and Placebo Turbuhaler, then Placebo Diskus and Placebo Turbuhaler
Drug: Formoterol · Drug: Salmeterol · Drug: Placebo
Salmeterol Diskus 50 μg and Placebo Turbuhaler first, then Placebo Diskus and Placebo Turbuhaler, then Formoterol Turbuhaler 9 μg and Placebo Diskus
Drug: Formoterol · Drug: Salmeterol · Drug: Placebo
Placebo Diskus and Placebo Turbuhaler first,then Formoterol Turbuhaler 9 μg and Placebo Diskus, then Salmeterol Diskus 50 μg and Placebo Turbuhaler
Drug: Formoterol · Drug: Salmeterol · Drug: Placebo
Formoterol Turbuhaler 9 μg and Placebo Diskus first, then Placebo Diskus and Placebo Turbuhaler, then Salmeterol Diskus 50 μg and Placebo Turbuhaler
Drug: Formoterol · Drug: Salmeterol · Drug: Placebo
Salmeterol Diskus 50 μg and Placebo Turbuhaler first, then Formoterol Turbuhaler 9 μg and Placebo Diskus, then Placebo Diskus and Placebo Turbuhaler
Drug: Formoterol · Drug: Salmeterol · Drug: Placebo
Placebo Diskus and Placebo Turbuhaler first, then Salmeterol Diskus 50 μg and Placebo Turbuhaler, then Formoterol Turbuhaler 9 μg and Placebo Diskus
Drug: Formoterol · Drug: Salmeterol · Drug: Placebo
Formoterol Turbuhaler 9 μg and Placebo Diskus
Salmeterol Diskus 50 μg and Placebo Turbuhaler
Placebo Diskus and Placebo Turbuhaler
FEV1(Forced Expiratory Volume in 1 Second) Measured by Spirometry 5 Minutes Post Dose
FEV1(Forced Expiratory Volume in 1 second) measured by spirometry 5 minutes post dose, percentage change versus pre dose FEV1
Time frame: Pre-dose and 5 minutes post-dose
Average FEV1 During the First 15 Minutes Post Dose
Average FEV1 during the first 15 minutes post dose, change versus pre dose FEV1
Time frame: Pre dose and 15 minutes post dose
Average FEV1 During 120 Minutes Post Dose
Average FEV1 during 120 minutes post dose, change versus pre dose FEV1
Time frame: Pre dose and 120 minutes post dose
Percentage of Patients Who Has Achieved at Least 12 % Increase in FEV1
Percentage of patients who has achieved at least 12 % increase in FEV1 at each time point between 5 to 120 minutes post dose, change versus pre dose FEV1
Time frame: Pre dose, 5, 10, 15, 20, 30, 40, 50, 60 and 120 minutes post dose
Adverse Events
Number of participants with at least 1 AE.
Time frame: At baseline and at each day of treatment
Patients recruited at 14 clinics in 3 countries: Sweden (4 clinics); Italy (6 clinics); Spain (6 clinics)between January and May 2010
| Milestone | Formoterol, Then Salmeterol, Then Placebo | Salmeterol, Then Palcebo, Then Formoterol | Placebo, Then Formoterol, Then Salmeterol | Formoterol, Then Placebo, Then Salmeterol | Salmeterol, Then Formoterol, Then Placebo | Placebo, Then Salmeterol, Then Formoterol |
|---|---|---|---|---|---|---|
| Started | 21 | 19 | 16 | 18 | 17 | 18 |
| Completed | 21 | 19 | 16 | 18 | 17 | 18 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Formoterol, Then Salmeterol, Then Placebo | Salmeterol, Then Palcebo, Then Formoterol | Placebo, Then Formoterol, Then Salmeterol | Formoterol, Then Placebo, Then Salmeterol | Salmeterol, Then Formoterol, Then Placebo | Placebo, Then Salmeterol, Then Formoterol |
|---|---|---|---|---|---|---|
| Started | 21 | 19 | 16 | 18 | 17 | 18 |
| Completed | 21 | 19 | 16 | 18 | 17 | 18 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Formoterol, Then Salmeterol, Then Placebo | Salmeterol, Then Palcebo, Then Formoterol | Placebo, Then Formoterol, Then Salmeterol | Formoterol, Then Placebo, Then Salmeterol | Salmeterol, Then Formoterol, Then Placebo | Placebo, Then Salmeterol, Then Formoterol |
|---|---|---|---|---|---|---|
| Started | 21 | 19 | 16 | 18 | 17 | 18 |
| Completed | 21 | 19 | 16 | 18 | 17 | 18 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Formoterol, Then Salmeterol, Then Placebo | Salmeterol, Then Palcebo, Then Formoterol | Placebo, Then Formoterol, Then Salmeterol | Formoterol, Then Placebo, Then Salmeterol | Salmeterol, Then Formoterol, Then Placebo | Placebo, Then Salmeterol, Then Formoterol |
|---|---|---|---|---|---|---|
| Started | 21 | 19 | 16 | 18 | 17 | 18 |
| Completed | 21 | 18 | 16 | 18 | 17 | 18 |
| Not completed | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Formoterol, Then Salmeterol, Then Placebo | Salmeterol, Then Palcebo, Then Formoterol | Placebo, Then Formoterol, Then Salmeterol | Formoterol, Then Placebo, Then Salmeterol | Salmeterol, Then Formoterol, Then Placebo | Placebo, Then Salmeterol, Then Formoterol |
|---|---|---|---|---|---|---|
| Started | 21 | 18 | 16 | 18 | 17 | 18 |
| Completed | 21 | 18 | 16 | 18 | 17 | 18 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
FEV1(Forced Expiratory Volume in 1 second) measured by spirometry 5 minutes post dose, percentage change versus pre dose FEV1
| percentage change | Formoterol | Salmeterol | Placebo |
|---|---|---|---|
| FEV1(Forced Expiratory Volume in 1 Second) Measured by Spirometry 5 Minutes Post Dose | 1.072 (1.055 to 1.088) | 1.041 (1.025 to 1.057) | 1.007 (0.992 to 1.023) |
Average FEV1 during the first 15 minutes post dose, change versus pre dose FEV1
| percentage change | Formoterol | Salmeterol | Placebo |
|---|---|---|---|
| Average FEV1 During the First 15 Minutes Post Dose | 1.064 (1.052 to 1.077) | 1.041 (1.030 to 1.053) | 1.012 (1.001 to 1.024) |
Average FEV1 during 120 minutes post dose, change versus pre dose FEV1
| percentage change | Formoterol | Salmeterol | Placebo |
|---|---|---|---|
| Average FEV1 During 120 Minutes Post Dose | 1.096 (1.079 to 1.112) | 1.082 (1.066 to 1.098) | 1.014 (0.999 to 1.029) |
Percentage of patients who has achieved at least 12 % increase in FEV1 at each time point between 5 to 120 minutes post dose, change versus pre dose FEV1
| Percentage of Participants | Formoterol | Salmeterol | Placebo |
|---|---|---|---|
| 5 min | 23.1 | 9.2 | 6.4 |
| 10 min | 38.0 | 17.6 | 7.3 |
| 15 min | 39.8 | 23.9 | 9.2 |
| 20 min | 44.4 | 27.5 | 10.1 |
| 30 min | 45.4 | 32.1 | 13.8 |
| 40 min | 49.1 | 36.7 | 15.6 |
| 50 min | 53.7 | 40.4 | 16.5 |
| 60 min | 54.6 | 43.1 | 18.3 |
| 120 min | 55.6 | 48.6 | 20.2 |
Number of participants with at least 1 AE.
| Participants | Formoterol | Salmeterol | Placebo |
|---|---|---|---|
| Adverse Events | 6 | 6 | 2 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Formoterol | — | 0/108 (0%) | 0/108 (0%) |
| Salmeterol | — | 0/109 (0%) | 0/109 (0%) |
| Placebo | — | 0/109 (0%) | 0/109 (0%) |
| Age Continuous(years) | Entire Study Population |
|---|---|
| Mean | 66.5 (41.0 to 84.0) |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 28 |
| Male | 81 |
The record gives a start of Jan 2010, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Formoterol
Pulmonary Disease, Chronic Obstructive →